Skip to main content
OpenTrials
Completed

NCT Number: NCT02273908

PROs in Chronic Low Back Pain Patients With Accompanying Lower Limb Pain (Neuropathic Component) Treated With Pregabalin

The purpose of this study is to evaluate the effect of pregabalin comparing with the conventional analgesic care in chronic low back pain patients with accompanying lower limb pain (neuropathic component) treated in primary care settings under routine clinical practice.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Low-back Pain Back Pain Low Back Pain Nervous System Diseases Neuralgia Neurologic Manifestations Neuromuscular Diseases Pain Pathological Conditions, Signs and Symptoms Peripheral Nervous System Diseases Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Kimura Clinic, Nagoya, Aichi-ken, Japan

Loading trial locations.

About this study

Rational and background :

The care for low back pain associated with neuropathic pain is a problem often encountered in daily outpatient.

And the care effectiveness has been frequently evaluated by the patients directly, because the pain would be felt by patients themselves.

On the view of those, we decided to investigate the clinical treatment outcome of pregabalin or other analgesics medication for relief of pain and improvement of sleep interference and QOLs by Patient-reported outcomes.

Research question and objectives :

To evaluate the effect of pregabalin comparing with the conventional analgesic care in chronic low back pain patients with accompanying lower limb pain (neuropathic component) treated in primary care settings under routine clinical practice.

Study design:

This is an 8-week, multicenter prospective observational study. Subjects who have chronic low back pain patients with accompanying lower limb pain (with a neuropathic component) and meet all other entry criteria are enrolled at baseline in the duration of study. The analgesic treatment is determined by the clinical judgment of the physician in charge of patient management. This therapeutic choice is not related to the decision to take part in the study. All enrolled subjects will be received with analgesic treatment. The study requires 3 visits at least, baseline/enrollment visit, Week 4 visit and Week 8 visit (or discontinuation).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject who received the enough study information and signed informed consent form.
  • Subject who had chronic low back pain accompanying with lower limb pain from the knee to the ankle.
  • Subject is male or female patient ≥18 years old.
  • Subject who has complained low back pain for 3 months or more before Visit 1.
  • Subject who is refractory to prior analgesics for 3 months and more.
  • Subject who is able and willing to complete all study related assessment and comply with the study schedule and clinical procedures at clinic.
  • Subject whose pain Numeric Rating Scale(NRS) ≥ 5 at baseline (based on recall over the past week)

Exclusion criteria

  • Subject who, in the opinion of the investigator, was not likely to complete the trial for whatever reason.
  • Subject who has been already treated by pregabalin

Treatment and study plan

No intervention

Other

The study is observational

Primary outcomes

  1. Change From Baseline in Pain Related Sleep Interference Scale (PRSIS - Past Week Recall)

    Time frame: Baseline, Final Visit (Week 8)

    The Pain Related Sleep Interference Scale (past week recall) consists of an 11-point rating scale ranging from 0 (pain did not interfere with sleep) to 10 (pain completely interfered with sleep). Change the rating scale from baseline to week 8 in each group. Subjects are to describe how their pain has interfered with their sleep during the past week by choosing the appropriate number between 0 and 10.

Secondary outcomes

  1. Change From Baseline in Roland Morris Disability Questionnaire (RMDQ)-Total Score-

    Time frame: Baseline, Visit2 (Week4), Final Visit (Week8 or discontinuation)

    The RMDQ is an index of how well patients with low back pain are able to function with regard to daily activities. The score for the index ranges from 0 to 24 with a lower score indicating better function.

  2. Change From Baseline in Roland Morris Disability Questionnaire (RMDQ)-Japanese Standardized Score-

    Time frame: Baseline, Visit2 (Week4), Final Visit (Week8 or discontinuation)

    The RMDQ is an index of how well patients with low back pain are able to function with regard to daily activities. The score for the index ranges from 0 to 24 with a lower score indicating better function.

  3. Change From Baseline in Pain Numeric Rating Scale (Pain NRS - Past Week Recall)

    Time frame: Baseline, Visit2 (Week4), Final Visit (Week8 or discontinuation)

    The Pain NRS (past week recall) consists of an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst possible pain). Subjects are asked to describe their average pain during the past week by choosing the appropriate number between 0 and 10.

  4. Change From Baseline in Euro Qol 5-Dimensions (EQ-5D-5L)-QOL-Score-

    Time frame: Baseline, Visit2 (Week4), Final Visit (Week8 or discontinuation)

    The EQ-5D-5L is a copyrighted, subject-completed questionnaire designed to assess health-related quality of life in terms of a single index value or utility score. The Health State Profile is designed to record the subject's level of current health for five domains comprising a health profile: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Responses from the five domains are used to calculate a single utility index value.; 1 indicates better health state (no problems); 5 indicates worst health state (eg, "confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile; from 11111 to 55555. Score is transformed and results in a total score range -0.025 to 1.000; higher score indicates a better health state.

  5. Change From Baseline in Euro Qol 5-Dimensions (EQ-5D-5L)-Visual Analogue Scale -

    Time frame: Baseline, Visit2 (Week4), Final Visit (Week8 or discontinuation)

    The EQ-5D-5L is a copyrighted, subject-completed questionnaire designed to assess health-related quality of life in terms of a single index value or utility score. There are two components to the EQ-5D-5L: A Health State Profile and a Visual Analogue Scale (VAS). Recent guidance suggests that the Health State Profile and VAS should be administered together.

    The Visual Analogue Scale (VAS) is designed to rate the subject's current health state on a scale from 0 to 100 where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.

  6. Clinical Global Impression of Change (CGIC)

    Time frame: Final Visit (Week8 or discontinuation)

    The CGIC assessment includes one question (1-7 scale) inquiring about the subject's improvement considering their current disease state.; range from 1 (very much improved) to 7 (very much worse).

  7. Patient Global Improvement of Change (PGIC)

    Time frame: Final Visit (Week8 or discontinuation)

    The PGIC is a subject-rated instrument that measures change in the subject's overall status on a 7-point scale. Scores range from 1 (very much improved) to 7 (very much worse).

  8. Work Productivity and Activity Impairment Scale (WPAI:LBP)

    Time frame: Final Visit (Week8 or discontinuation)

    The WPAI: LBP is a self-administered questionnaire that measures the effect of general health and symptom severity on work productivity and regular activities. Subscale scores include Percent work time missed due to pain (PWP), Percent overall work impairment (PWI), Percent work productivity impairment due to pain (PWPI), Percent overall activity impairment (PAI). Each subscale score is expressed as an impairment percentage (0-100) where higher numbers indicate greater impairment and less productivity. Here, "n" signifies "Number of participants" for Baseline.

    In this study, the WPAI: LBP will measure the effect of the patient's Chronic Low Back Pain (CLBP) with accompanying lower limb pain (neuropathic component) on work productivity and regular activities.

Other outcomes

  1. Number of Patients With Adverse Events

    Time frame: Visit2(week4),Final Visit(Week8 or discontinuation)

Sponsors and collaborators

Lead sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Industry

Registry information

Official study title

Patient-reported-outcomes(PROs) in Chronic Low Back Pain Patients With Accompanying Lower Limb Pain (Neuropathic Component) Treated With Pregabalin in Primary Care Settings

Acronym: PRO

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Oct 24, 2014
Registry last updated
Feb 3, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.